Huadong Medicine signed an $83 million agreement to acquire China/Western Asia rights for a diabetes 2 treatment developed by vTv Therapeutics of North Carolina . TTP273 is an oral GLP-1r agonist. Huadong will pay $8 million upfront and be responsible for an additional $75 million in milestones plus royalties. TTP273 has successfully completed a US Phase II trial, providing a statistically significant reduction in HbA1c in type 2 diabetics. More details.... Stock Symbols: (SZE: 000963) (NSDQ: VTVT) Share this with colleagues: // //